PT  - JOURNAL ARTICLE
AU  - Takoutsing, Berjo Dongmo
AU  - Touzet, Alvaro Yanez
AU  - Park, Jay J.
AU  - Lee, Seong Hoon
AU  - Bligh, Emily R.
AU  - Egiz, Abdullah
AU  - Gillespie, Conor S.
AU  - Figaji, Anthony
AU - the Neurology and Neurosurgery Interest Group
TI  - Management and outcomes of myelomeningocele-associated hydrocephalus in low- and middle-income countries: a systematic review and meta-analysis protocol
AID  - 10.1101/2022.06.13.22276320
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.13.22276320
4099  - http://medrxiv.org/content/early/2022/11/21/2022.06.13.22276320.short
4100  - http://medrxiv.org/content/early/2022/11/21/2022.06.13.22276320.full
AB  - Introduction Hydrocephalus and myelomeningocele (MMC) place disproportionate burdens of disease on low and middle-income countries (LMICs). MMC-associated hydrocephalus and its sequelae result in a spectrum of severely devastating clinical manifestations, for which LMICs are disproportionately unprepared in terms of human, capital, and technological resources. This study aims to review and compare the management and outcomes of infant MMC-associated hydrocephalus in LMICs and high-income countries.Methods and analysis This systematic review and meta-analysis will follow the PRISMA 2020 guidelines. The following databases will be searched without restrictions on language, publication date, or country of origin: EMBASE, MEDLINE, The Cochrane Library, Global Index Medicus, African Journals Online, and SciELO. All peer-reviewed studies of primary data reporting management and outcomes of infant MMC-associated hydrocephalus will be included. Where high-quality homogeneous studies exist, meta-analyses will be conducted to compare the management and outcomes of MMC-associated hydrocephalus across socioeconomic and geographic regions of the world. The primary outcome will be treatment failure of the first-line hydrocephalus treatment, which we defined operationally as the performance of a second intervention for the same reason as the first. Secondary outcomes include time to failure, rates of mortality, and postoperative complications.Ethics and dissemination Ethical approval was not applicable because this study does not involve human participants. Dissemination strategies will include publication in a peer-reviewed journal, oral and poster presentations at conferences, and an interactive web application to facilitate interaction with the findings and promote the discussion and sharing of findings on social media.Strengths and limitations of this studyThis review focuses on multiple treatment modes of a well-defined disease population.Six electronic databases that are commonly used across both high- and low-income countries will be searched.No restrictions on language, location, or publication date were placed during screening.Unpublished studies will not be sought.The representativeness of the sample will rely on the quality of reporting of myelomeningocoele-associated hydrocephalus in the literature.Only one operational definition of treatment failure—‘the performance of a second intervention for the same reason as the first’—will be sought.An interactive web application dashboard will be developed to facilitate the transparent interaction with our methods and findings and promote scientific discussion and scrutiny.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript